Italian investigators sought to determine if combining R-CHOP plus ibrutinib followed by ibrutinib maintenance improved PFS in treatment-naive patients aged 65 years and younger with high-risk ABC ...

Please provide your email address to receive an email when new articles are posted on . Researchers observed significantly longer PFS with ibrutinib plus venetoclax vs. ibrutinib plus placebo. No new ...

Ibrutinib, a BTK inhibitor, is effective in treating relapsed CLL, with combination therapies improving response rates. Combination therapy with ibrutinib and venetoclax, guided by MRD, enhances ...

A study in a mouse model found that mice receiving chimeric antigen receptor (CAR)-T immunotherapy plus ibrutinib demonstrated longer overall survival and reduced cytokine production than the mice not ...

Ibrutinib is the first approved Bruton’s tyrosine kinase (BTK) inhibitor to demonstrate statistically meaningful outcomes versus autologous stem cell transplant (ASCT) for the frontline treatment of ...

Chronic lymphocytic leukemia (CLL) is the most common form of blood cancer (leukemia) in the Western world, affecting approximately 1.2% of all cancer patients. This type of cancer starts with the ...

Chronic lymphocytic leukemia (CLL) is frequently complicated by secondary autoimmune cytopenias (AICs). Ibrutinib is an irreversible inhibitor of Bruton’s tyrosine kinase approved for the treatment of ...

Please provide your email address to receive an email when new articles are posted on . CLL is the most common leukemia among adults. Standard treatment is combination chemoimmunotherapy with regimens ...

The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) today announced results from an extended follow-up analysis of patients in its randomized Phase 3 clinical trial, E1912. The results show that the ...

In a head-to-head comparison of two Food and Drug Administration-approved drugs for the treatment of relapsed chronic lymphocytic leukemia, ibrutinib significantly outperformed ofatumumab as a ...

About 10 percent of patients with chronic lymphocytic leukemia discontinued therapy with the Bruton tyrosine kinase inhibitor drug ibrutinib because of disease progression during clinical trials, ...